Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Rare Disease Voucher Program Faces Expiration

Executive Summary

Stakeholders push Congress to renew program, although 21st Century Cures route unlikely.

Advertisement

Related Content

Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee
GDUFA II Will Include Small Business Relief, Priority ANDA Reviews
Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems
NIH's Zika Vaccine Faces Funding Challenge After Skipping Industry Partnership
Tracking The Priority Review Vouchers
Priority Review Vouchers Appear To Be Dropping In Price
No FDA Funding Boost In Senate HELP GOP Members' Innovation Bill
Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says
Priority Review Vouchers, FDA Funding Win In Omnibus Budget Deal
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119107

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel